Similar articles

• Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP).

  Rylander R, Beijer L, Lantz RC, Burrell R, Sedivy P. Rylander R, et al. Int Arch Allergy Appl Immunol. 1988;86(3):303-7. doi: 10.1159/000234588. Int Arch Allergy Appl Immunol. 1988. PMID: 3403044
• Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.

  Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H. Yamada T, et al. Arch Int Pharmacodyn Ther. 1990 Nov-Dec;308:123-36. Arch Int Pharmacodyn Ther. 1990. PMID: 2099131
• Production of platelet-activating factor in inflammatory exudate.

  Oh-ishi S, Imai Y, Hayashi M. Oh-ishi S, et al. J Lipid Mediat. 1992 Jun-Jul;5(2):115-20. J Lipid Mediat. 1992. PMID: 1525350
• Platelet-activating factor antagonists and ocular inflammation.

  Bazan HE, Tao Y, Hurst JS. Bazan HE, et al. J Ocul Pharmacol. 1994 Spring;10(1):319-27. doi: 10.1089/jop.1994.10.319. J Ocul Pharmacol. 1994. PMID: 8207336 Review. No abstract available.
• [Platelet activating factor (PAF)--a new chemical mediator of inflammation].

  Satouchi K. Satouchi K. Seikagaku. 1983;55(3):160-6. Seikagaku. 1983. PMID: 6350499 Review. Japanese. No abstract available.